Total
0
Shares
Ambassador, Michael Clarke
Source: Respiri
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Respiri (RSH) begins selling its wheezo device across more than 570 pharmacies within the Sigma Healthcare network across Australia
  • Sigma is a respected wholesaler and the owner of pharmacy brands such as Amcal, Guardian, Discount Drug Store and Chemist King
  • The wheezo device is used to monitor and manage the symptoms of asthma and it helps sufferers gain a better understanding of their condition
  • Respiri is now in discussions with a number of other pharmacies and will make further announcements once discussions are finalised and orders begin
  • Shares in Respiri are up 7.14 per cent and are trading at 7.5 cents at 11:50 am AEST

Respiri (RSH) has begun selling its wheezo device across more than 570 pharmacies within the Sigma Healthcare network across Australia.

Sigma is a respected wholesaler and the owner of pharmacy brands such as Amcal, Guardian, Discount Drug Store and Chemist King.

“Sigma is a well-known and trusted pharmacy business whose brands have a long history in the Australian market, that patients frequent when seeking healthcare management advice,” Respiri CEO and Managing Director Marjan Mikel said.

“We look forward to a long and mutual beneficial partnership with Sigma’s retail brands that will deliver better health outcomes for patients with asthma.”

Respiri’s wheezo device is used to monitor and manage the symptoms of asthma.

It provides asthma management diary features, medication usage and reminders, as well as information about symptoms and triggers to help asthma sufferers gain a better understanding of how their condition affects them.

Data can then be shared with caregivers, physicians and other healthcare professionals.

Respiri is now in discussions with a number of other pharmacies and will make further announcements once discussions are finalised and orders begin.

Shares in Respiri were up 7.14 per cent and were trading at 7.5 cents at 11:50 am AEST.

RSH by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).